Clinical Trials Browser

Phase 1/2 × Ear Diseases × Acetylcysteine × Clear all

NCT04291209 2023-09-06

Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

Phase 1/2 Unknown

Deafness, Ear Diseases, Hearing Loss, Sensorineural, Hearing Loss